SCHEMBL2180897

SCHEMBL2180897

NOC(=O)CCCCCC(=O)ON

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.42
TSHR P16473 3/20 0.41
LMNA P02545 6/20 0.40
NFKB1 P19838 1/20 0.40
PMP22 Q01453 1/20 0.40
PAM P19021 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
PLG P00747 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
SLC6A2 P23975 1/20 0.38
RECQL P46063 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1A2 P05177 1/20 0.37
MAPT P10636 2/20 0.37
MAPK1 P28482 1/20 0.37
PAOX Q6QHF9 1/20 0.36
HDAC3 O15379 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065353 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL515782 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL27738121 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL27672248 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL9593894 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL1064431 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL27705302 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL9593713 1.00 DGKA (0.42) DGKATSHRLMNANFKB1PMP22
SCHEMBL27569510 0.97 DGKA (0.41) DGKATSHRLMNANFKB1PMP22
SCHEMBL28175756 0.97 DGKA (0.41) DGKATSHRLMNANFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113252806-A Application of S-adenosyl homocysteine in preparation of product for diagnosing or treating kawasaki disease 嘉兴学院 2021-08-13 CN claimed
US-9101662-B2 Compositions with modulating agents FOAMIX PHARMACEUTICALS LTD. (IL) 2015-08-11 US claimed
US-8795693-B2 Compositions with modulating agents FOAMIX LTD. (IL) 2014-08-05 US claimed
WO-2010017405-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN HELLER ADAM (US) 2010-02-11 WO claimed
CN-101619296-A Streptomyces lactis and application thereof GUANGDONG INST MICROBIOLOGY 2010-01-06 CN claimed
EP-2120555-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN Heller, Adam (US) 2009-11-25 EP claimed
EP-2097065-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS Foamix Ltd. (IL) 2009-09-09 EP claimed
CN-101525586-A Streptomyces caeruleatus GIMN4.002 and application thereof GUANGDONG INST MICROBIOLOGY 2009-09-09 CN claimed
WO-2008152444-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS FOAMIX LTD. (US) 2008-12-18 WO claimed
US-20080287866-A1 Methods and compositions for the treatment of pain HELLER ADAM 2008-11-20 US claimed
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions FOAMIX LTD. (IL) 2008-08-28 US claimed
WO-2008094664-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN HELLER ADAM (US) 2008-08-07 WO claimed
EP-0848592-B1 ANTISTRESS AGENTS FOR AQUATIC ANIMALS BAENSCH TETRA WERKE (DE) 2000-11-02 EP claimed
CN-118772242-A CD137 specific bicyclic peptide ligands 拜斯科技术开发有限公司 2024-10-15 CN disclosed
CN-111183147-B CD137 specific bicyclic peptide ligands 拜斯科技术开发有限公司 2024-07-05 CN disclosed
CN-117615794-A Checkpoint inhibitors conjugated to IL-2 and uses thereof 明峰治疗股份公司 2024-02-27 CN disclosed
US-4439199-A TO ACTIVATE AN IMMUNE RESPONSE ALZA CORPORATION (US) 1984-03-27 US disclosed
US-4389486-A SACCHAROPOLYSPORA HIRSUTA, WICH PRODUCES ANTIBIOTIC KA-6606 BY FERMENTATION KOWA COMPANY, LTD. (JP) 1983-06-21 US disclosed
US-4328211-A Antibiotic Actinomadura-L-31 A, B KAKEN CHEMICAL CO., LTD. (JP) 1982-05-04 US disclosed
US-3991107-A Haloamine transfer NATIONAL PATENT DEVELOPMENT CORPORATION (US) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions CUTA, SLTM, SMO DGKA 53/4885TSHR 4100/4885LMNA 1023/4885
US-20080287866-A1 Methods and compositions for the treatment of pain ACHE, S100P, P2RX3 DGKA 1354/4885TSHR 4339/4885LMNA 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.